Quantum Leap award applications are due September 30th.
Access to innovative molecules and experimental reagents is an essential part of translating disease hypotheses into potential therapies.
We plan to expand our existing capabilities in biologics to enable access to a wider range of molecules for studying diverse proteins and drug targets with the optimal chemical tools.
Specifically, this new platform will position the IBRI to:
Your donation will help lead to solutions to major health challenges such as diabetes, cardiometabolic disease and poor nutrition.